Nektar Upgraded To Neutral From Sell At Goldman Sachs
March 30, 2020 at 08:16 AM EDT
Goldman Sachs analyst Paul Choi upgraded Nektar Therapeutics to Neutral from Sell with a price target of $20, up from $18.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|